Partridge and embryonated partridge egg as new preclinical models for candidiasis

Tavakkoli, Hadi; Khosravi, Ahmad; Sharifi, Iraj; Shahshahan, Zahra; Salarkia, Ehsan; Kheirandish, Reza; Dehghantalebi, Kazem; Jajarmi, Maziar; Mosallanejad, Seyedeh Saedeh; Dabiri, Shahriar; Keyhani, Alireza

doi:10.1038/s41598-021-81592-y

Cited by 4 publications

(2 citation statements)

References 56 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At first, the total RNA of YSM vasculature was extracted by triazole (YTzol Pure RNA, Iran), and cDNA was synthesized by using the TaKaRa kit, finally, by using the specific primers and reference gene sequences listed in Table 1 . The qPCR reaction was done using Parstous RTSYBR Green in Rotor-Gene Q 37 , 38 .…”

Section: Methodsmentioning

confidence: 99%

Comparison of cytotoxicity of Miltefosine and its niosomal form on chick embryo model

Seyedi,

Sharifi,

Khosravi

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

Various drugs have been used for the treatment of leishmaniasis, but they often have adverse effects on the body's organs. In this study, we aimed to explore the effects of one type of drug, Miltefosine (MIL), and its analogue or modifier, liposomal Miltefosine (NMIL), on several fetal organs using both in silico analysis and practical tests on chicken embryos. Our in silico approach involved predicting the affinities of MIL and NMIL to critical proteins involved in leishmaniasis, including Vascular Endothelial Growth Factor A (VEGF-A), the Kinase insert domain receptor (KDR1), and apoptotic-regulator proteins (Bcl-2-associate). We then validated and supported these predictions through in vivo investigations, analyzing gene expression and pathological changes in angiogenesis and apoptotic mediators in MIL- and NMIL-treated chicken embryos. The results showed that NMIL had a more effective action towards VEGF-A and KDR1 in leishmaniasis, making it a better candidate for potential operative treatment during pregnancy than MIL alone. In vivo, studies also showed that chicken embryos under MIL treatment displayed less vascular mass and more degenerative and apoptotic changes than those treated with NMIL. These results suggest that NMIL could be a better treatment option for leishmaniasis during pregnancy.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparison of cytotoxicity of Miltefosine and its niosomal form on chick embryo model

Seyedi,

Sharifi,

Khosravi

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Molecular dynamics (MD) simulations were done by Gromacs 5.4.1 and the amber force field ( Wang et al, 2004 ; Van Der Spoel et al, 2005 ). The GROMACS package was applied for molecular dynamics simulations by various researchers ( Jacob et al, 2017 ; Tavakkoli et al, 2021 ; Zhang et al, 2022 ). The docked structures of the EMP with Bax and Bcl-2 were placed inside a dodecahedron box and were solvated withTIP3P water molecules.…”

Section: Methodsmentioning

confidence: 99%

Empagliflozin induces apoptotic-signaling pathway in embryonic vasculature: In vivo and in silico approaches via chick’s yolk sac membrane model

Mosallanejad

Mahmoodi²,

Tavakkoli³

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

The present investigation was conducted to evaluate the vascular-toxicity of empagliflozin (EMP) in embryonic vasculature. Firstly, the vascular-toxicity of the drug as well as its interaction with apoptotic regulator proteins was predicted via in silico approach. In the next step, the apoptotic-signaling pathway in embryonic vasculature was evaluated using a chick’s YSM model. In silico simulation confirmed vascular-toxicity of EMP. There was also an accurate affinity between EMP, Bax and Bcl-2 (−7.9 kcal/mol). Molecular dynamics assay revealed complex stability in the human body conditions. Furthermore, EMP is suggested to alter Bcl-2 more than BAX. Morphometric quantification of the vessels showed that the apoptotic activity of EMP in embryonic vasculature was related to a marked reduction in vessel area, vessel diameter and mean capillary area. Based on the qPCR and immunohistochemistry assays, enhanced expression level of BAX and reduced expression level of Bcl-2 confirmed apoptotic responses in the vessels of the YSM. We observed that induction of an apoptotic signal can cause the embryonic defect of the vascular system following EMP treatment. The acquired data also raised suspicions that alteration in apoptotic genes and proteins in the vasculature are two critical pathways in vascular-toxicity of EMP.

show abstract

Delivery Route Considerations for Designing Antigen‐Specific Biomaterial Strategies to Combat Autoimmunity

Ackun-Farmmer

Jewell

2023

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Motivating the Development of Antigen-Specific ImmunotherapiesAutoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CD), and many others develop when the immune system mistakenly recognizes self-antigens as foreign, resulting in an orchestrated attack of host tissues. MS is a demyelinating disease that affects the central nervous system (CNS), RA is a chronic inflammatory joint disorder that can affect other tissues and organs, and T1D is a chronic condition whereby the pancreas produces little or no insulin. Complications from T1D can impact other tissues and organs. CD is a chronic digestive autoimmune disease that is triggered by gluten consumption, resulting in damage to the small intestine. The exact causes of autoimmune diseases are only partially understood. However, biological sex, [1,2] genetics, [3,4] existing autoimmune disease, [5] lifestyle (i.e., smoking, obesity, and exposure), [6][7][8][9][10][11] certain medications, [12] and certain infections [13][14][15][16][17] have been linked with the development of autoimmune diseases. For example, most autoimmune diseases affect more female than male patients, but the reason for this bias is unclear. [1] In MS, risk gene variant, HLA-DRB1*15:01, increases risk for patients, [18] and infection by Epstein-Barr virus (EBV) is associated with increased risks of MS, RA, and other autoimmune diseases. [13][14][15] These are currently no cures for these diseases, creating chronic battles that affect patient quality of life and require life-long compliance. Owing to the complex immunopathology of autoimmune disease, current treatments, even monoclonal antibodies, are not able to distinguish between normal and self-reactive cells. These therapies exploit distinct parenteral (e.g., intravenous [IV], subcutaneous [S.C.], intramuscular (IM), intradermal (ID), transdermal, intranodal) or mucosal (e.g., oral, intranasal (IN), pulmonary, sublingual, ocular) delivery routes to reduce disease severity. [19][20][21][22][23] For example, Ocrelizumab (Ocrevus, Genentech), a recombinant antibody that binds to CD20 on B lymphocytes to treat MS, is administered via IV injection and associated with risk of infections and allergic responses in certain patients. [19] Methotrexate, a first-line disease-modifying antirheumatic drug, is provided orally or S.C. but can lead to liver and lung damage and

show abstract

Partridge and embryonated partridge egg as new preclinical models for candidiasis

Cited by 4 publications

References 56 publications

Comparison of cytotoxicity of Miltefosine and its niosomal form on chick embryo model

Comparison of cytotoxicity of Miltefosine and its niosomal form on chick embryo model

Empagliflozin induces apoptotic-signaling pathway in embryonic vasculature: In vivo and in silico approaches via chick’s yolk sac membrane model

Delivery Route Considerations for Designing Antigen‐Specific Biomaterial Strategies to Combat Autoimmunity

Contact Info

Product

Resources

About